Cohort Study of the Clinical Course of Macular Diseases in Kagawa
Cohort Study of the Clinical Course of Macular Diseases in Kagawa
Macular diseases often cases severe visual impairment. Recent clinical introduction of
 anti-vascular endothelial growth factor agents may change the clinical course of various
 macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal
 vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy
 (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic
 macular edema (DME), and so forth. The advance in vitrectomy improve visual outcomes in some
 maculae diseases, including epiretinal membrane (ERM), macular hole (MH), vitreomacular
 traction syndrome (VMTS).

 Patients with such macular diseases are registered and are followed up for 5 years with
 appropriate treatment for each patient. By the analysis of the correlation between initial
 examinations and final visual acuity, factors associated with good visual prognosis will be
 elucidated.
Inclusion Criteria:

 -  Patients who visit Department of Ophthalmology, Kagawa University Hospital with
 macular diseases, such as AMD, PCV, RAP, RVO, DME, ERM, MH, VMTS.

 -  Patients who are agreed with the participation of this study.

 Exclusion Criteria:

 -  None